A review on cardiovascular effects of newer hypoglycemic medications.

A review on cardiovascular effects of newer hypoglycemic medications. Ann Med. 2017 May 25;:1-27 Authors: Cutshall BT, Twilla JD, Olinger AS, Oliphant CS Abstract Cardiovascular disease is the most prevalent cause of morbidity and mortality in diabetic patients. Improvement in cardiovascular complications with glycemic control and managing cardiovascular risk factors is well established. However, the impact of hypoglycemic medications on cardiovascular disease is of increasing importance. In 2008 the U.S. Food and Drug Administration issued study regulations for hypoglycemic agents after rosiglitazone was shown to increase the incidence of myocardial infarction, and the European Medicines Agency provided their own guidance in 2012. As a result, multiple studies have been published evaluating the cardiovascular safety of newer hypoglycemic medications. Empagliflozin and liraglutide are among the newer agents that have shown cardiovascular benefit and are now recommended for patients with cardiovascular disease or are at an increased risk of cardiovascular disease per the 2017 American Diabetes Association Guidelines. Given the influx of new literature and other ongoing studies, it is important to understand the cardiovascular safety of newer hypoglycemic medications. The purpose of this article is to provide a comprehensive review of clinical trials conducted evaluating cardiovascular outcomes of newer hypoglycemic medications and the...
Source: Annals of Medicine - Category: Internal Medicine Tags: Ann Med Source Type: research